New mRNA therapy targets tough autoimmune cases
NCT ID NCT06747156
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This early-phase study tests a new mRNA-based treatment (ABO2203) for people with autoimmune diseases that haven't improved with standard care. The therapy uses mRNA to produce a protein that helps the immune system attack harmful cells. The main goal is to check safety and tolerability in 66 adults, with a secondary look at how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact
Contact
-
Ruijin Hospital
RECRUITINGShanghai, China
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, 430022, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.